HRS-3738
Phase 1UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Conditions
Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Trial Timeline
Jun 17, 2022 → Dec 30, 2024
NCT ID
NCT05363800About HRS-3738
HRS-3738 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma. The current trial status is unknown. This product is registered under clinical trial identifier NCT05363800. Target conditions include Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
6
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05363800 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma